A5076668753- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Dermatological and COVID-19 studies
- SARS-CoV-2 and COVID-19 Research
- Cardiac Imaging and Diagnostics
- COVID-19 and healthcare impacts
- Viral Infections and Vectors
- Mosquito-borne diseases and control
- Atrial Fibrillation Management and Outcomes
- Vascular Procedures and Complications
- Celiac Disease Research and Management
- Cardiac Valve Diseases and Treatments
- Central Venous Catheters and Hemodialysis
- Venous Thromboembolism Diagnosis and Management
- Coronary Interventions and Diagnostics
- Pancreatitis Pathology and Treatment
- Cardiac Structural Anomalies and Repair
- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Pleural and Pulmonary Diseases
- Diabetes Management and Research
- Maternal and fetal healthcare
- Pneumothorax, Barotrauma, Emphysema
- Diabetes Treatment and Management
- Viral Infections and Immunology Research
Sarojini Naidu Medical College
2020-2024
Ysbyty Gwynedd Hospital NHS Trust
2024
Dinajpur Medical College
2020-2023
Methodist Hospital
2023
Hamad Medical Corporation
2021
Sri Devaraj Urs Medical College
2021
Foundation University Medical College
2021
Kasturba Medical College, Manipal
2021
Ross School
2021
Dow University of Health Sciences
2021
ABSTRACT Introduction PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing receptor activity, promoting clearance LDL‐C from the bloodstream. Over years, have been explored as adjunct therapies to statins or monotherapy in high‐risk cardiovascular patients. Aim This review aims provide an updated perspective on inhibitors, assessing their clinical efficacy, safety, and significance, especially light recent trials. Methods The examines role...